Literature DB >> 33440640

SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.

Yuichiro J Suzuki1, Sergiy G Gychka2.   

Abstract

The world is suffering from the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 uses its spike protein to enter the host cells. Vaccines that introduce the spike protein into our body to elicit virus-neutralizing antibodies are currently being developed. In this article, we note that human host cells sensitively respond to the spike protein to elicit cell signaling. Thus, it is important to be aware that the spike protein produced by the new COVID-19 vaccines may also affect the host cells. We should monitor the long-term consequences of these vaccines carefully, especially when they are administered to otherwise healthy individuals. Further investigations on the effects of the SARS-CoV-2 spike protein on human cells and appropriate experimental animal models are warranted.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; cell signaling; coronavirus; spike protein; vaccine

Year:  2021        PMID: 33440640      PMCID: PMC7827936          DOI: 10.3390/vaccines9010036

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  41 in total

1.  Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Adaani Frost; Robyn J Barst; Abby M Krichman; Michael D McGoon
Journal:  Transplantation       Date:  2010-08-15       Impact factor: 4.939

Review 2.  Drug-induced pulmonary arterial hypertension: a recent outbreak.

Authors:  David Montani; Andrei Seferian; Laurent Savale; Gérald Simonneau; Marc Humbert
Journal:  Eur Respir Rev       Date:  2013-09-01

3.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

Authors:  M Humbert; O Sitbon; A Yaïci; D Montani; D S O'Callaghan; X Jaïs; F Parent; L Savale; D Natali; S Günther; A Chaouat; F Chabot; J-F Cordier; G Habib; V Gressin; Z-C Jing; R Souza; G Simonneau
Journal:  Eur Respir J       Date:  2010-06-18       Impact factor: 16.671

4.  An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Authors:  Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel
Journal:  N Engl J Med       Date:  2020-07-14       Impact factor: 91.245

5.  Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

Authors:  T Thenappan; S J Shah; S Rich; L Tian; S L Archer; M Gomberg-Maitland
Journal:  Eur Respir J       Date:  2009-12-23       Impact factor: 16.671

6.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

Authors:  Mark J Mulligan; Kirsten E Lyke; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; Kathleen Neuzil; Vanessa Raabe; Ruth Bailey; Kena A Swanson; Ping Li; Kenneth Koury; Warren Kalina; David Cooper; Camila Fontes-Garfias; Pei-Yong Shi; Özlem Türeci; Kristin R Tompkins; Edward E Walsh; Robert Frenck; Ann R Falsey; Philip R Dormitzer; William C Gruber; Uğur Şahin; Kathrin U Jansen
Journal:  Nature       Date:  2020-08-12       Impact factor: 69.504

7.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

Review 8.  Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.

Authors:  Mahmoud Gheblawi; Kaiming Wang; Anissa Viveiros; Quynh Nguyen; Jiu-Chang Zhong; Anthony J Turner; Mohan K Raizada; Maria B Grant; Gavin Y Oudit
Journal:  Circ Res       Date:  2020-04-08       Impact factor: 17.367

9.  Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing.

Authors:  Xingzhi Xie; Zheng Zhong; Wei Zhao; Chao Zheng; Fei Wang; Jun Liu
Journal:  Radiology       Date:  2020-02-12       Impact factor: 11.105

10.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Authors:  Wanbo Tai; Lei He; Xiujuan Zhang; Jing Pu; Denis Voronin; Shibo Jiang; Yusen Zhou; Lanying Du
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

View more
  12 in total

1.  Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study.

Authors:  Celine Sze Ling Chui; Min Fan; Eric Yuk Fai Wan; Miriam Tim Yin Leung; Edmund Cheung; Vincent Ka Chun Yan; Le Gao; Yonas Ghebremichael-Weldeselassie; Kenneth K C Man; Kui Kai Lau; Ivan Chun Hang Lam; Francisco Tsz Tsun Lai; Xue Li; Carlos King Ho Wong; Esther W Chan; Ching-Lung Cheung; Chor-Wing Sing; Cheuk Kwong Lee; Ivan Fan Ngai Hung; Chak Sing Lau; Joseph Yat Sun Chan; Michael Kang-Yin Lee; Vincent Chung Tong Mok; Chung-Wah Siu; Lot Sze Tao Chan; Terence Cheung; Frank Ling Fung Chan; Anskar Yu-Hung Leung; Benjamin John Cowling; Gabriel Matthew Leung; Ian Chi Kei Wong
Journal:  EClinicalMedicine       Date:  2022-06-25

2.  Lysozyme Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Inflammation in Human Corneal Epithelial Cells.

Authors:  Yinting Song; Haokun Zhang; Yanfang Zhu; Xiao Zhao; Yi Lei; Wei Zhou; Jinguo Yu; Xue Dong; Xiaohong Wang; Mei Du; Hua Yan
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

3.  Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2.

Authors:  Ly Hien Doan; Li-Wei Chu; Zi-Yi Huang; Anh Thuc Nguyen; Chia-Yin Lee; Chien-Ling Huang; Yu-Fen Chang; Wen-Yu Hsieh; Trang Thi Huyen Nguyen; Chao-Hsiung Lin; Chun-Li Su; Tsung-Hsien Chuang; Jin-Mei Lai; Feng-Sheng Wang; Chia-Jui Yang; Hui-Kang Liu; Yueh-Hsin Ping; Chi-Ying F Huang
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

Review 4.  The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines.

Authors:  Mehrdad Mohammadi; Mohammad Shayestehpour; Hamed Mirzaei
Journal:  Braz J Infect Dis       Date:  2021-08-17       Impact factor: 3.257

Review 5.  Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis.

Authors:  Sarah Seeherman; Yuichiro J Suzuki
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

6.  Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.

Authors:  Mizanur Rahman; Martin Irmler; Sandeep Keshavan; Micol Introna; Johannes Beckers; Lena Palmberg; Gunnar Johanson; Koustav Ganguly; Swapna Upadhyay
Journal:  Viruses       Date:  2021-12-17       Impact factor: 5.048

7.  Why are we vaccinating children against COVID-19?

Authors:  Ronald N Kostoff; Daniela Calina; Darja Kanduc; Michael B Briggs; Panayiotis Vlachoyiannopoulos; Andrey A Svistunov; Aristidis Tsatsakis
Journal:  Toxicol Rep       Date:  2021-09-14

Review 8.  The Inflammatory Cytokine Imbalance for Miscarriage, Pregnancy Loss and COVID-19 Pneumonia.

Authors:  Fortunato Vesce; Chiara Battisti; Michele Crudo
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

9.  Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience.

Authors:  Jolanta Sauserienė; Ida Liseckienė; Vitalija Neverauskė; Eglė Šepetauskienė; Danielius Serapinas; Šarūnas Mačinskas; Brigita Šitkauskienė; Ieva Bajoriūnienė; Rūta Vaičiūnienė; Leonas Valius
Journal:  Medicina (Kaunas)       Date:  2022-03-17       Impact factor: 2.430

10.  Roles of existing drug and drug targets for COVID-19 management.

Authors:  Akeberegn Gorems Ayele; Engidaw Fentahun Enyew; Zemene Demelash Kifle
Journal:  Metabol Open       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.